Emeritus Professor Richard Henry AM. MB BS, Dip Clin Epi, MD, Hon DUniv (UNSW), FRACP, FRSN. Richard works as a consultant in health and higher education, following a long and distinguished career in medicine and academic leadership, including as Vice-President and Deputy Vice-Chancellor (Academic) of the University of New South Wales from 2006-2012. He joined UNSW in 1997 as the Foundation John Beveridge Professor of Paediatrics. He served as head of the School of Paediatrics and then of the School of Women’s and Children’s Health before moving to the role of Senior Associate Dean in the Faculty of Medicine. Richard was appointed a Member of the Order of Australia in 2007 for service to paediatric medicine as a clinician, researcher, educator and mentor, and serving in a range of roles with professional medical organisations. He is excited at the prospect of Luminesce Alliance as a paediatric precision medicine powerhouse able to reduce the time it previously took to deliver research findings to patients. Directorships: Director – Children’s Cancer Institute; Board member – Legal Aid NSW; Chairman of Trustees – Sydney Grammar School; Former Chair – Centre for Social Impact.

Dr Emily Mould is Head of Business Development at Children’s Cancer Institute. Emily moved from the UK to Australia nine years ago and spent 5 years working as a postdoctoral researcher and then in the program management team for the national precision medicine trial for children with cancer, Zero Childhood Cancer. In her current role, her team work with all researchers in the Children's Cancer Institute to support the development, advancement and protection of IP and assets, and pair them with new external academic or commercial partners to accelerate the translation of research into clinical impact. Emily is also involved in Children’s Cancer Institute’s advocacy and lobbying activities to government, has led submissions to multiple Parliamentary Inquiries and oversees the Institute’s partnerships with many external organisations.

Professor Ian Street is an internationally regarded leader in translational research, small molecule drug discovery and commercialization. Currently, he is Director of Therapeutic Innovation at the Children’s Cancer Institute, and an active consultant to the Australian Biotech Industry. Over his 36-year postdoctoral career, he has worked in industry and academia in the USA, Canada, and Australia, dedicating his time, energy, and innovation to bridging the gap between a “great idea” and the technical and commercial realities of translating that idea into a new medicine. To date, Ian’s career-spanning body of work has contributed to filing of 35 patent applications, publications in high impact journals, 7 investigational new drugs entering clinical trials, 2 FDA-approved drugs, over $151 million in research funding, over $426 million in milestones and royalty payments returned to Australian organizations, with the potential for an added $645 million in the future. Areas of Research: Drug Discovery and Commercialization, Biological Chemistry, Enzymology, Translational Cancer Biology

Associate Professor Antoine de Weck joined Children's Cancer Institute in January 2022 to establish and lead the Computationally Enabled Drug Discovery (CEDD) Group. CEDD is a hybrid (dry and wet) lab focusing on identifying new therapeutic vulnerabilities in childhood cancers, on identifying new or existing compounds capable of targeting those vulnerabilities, and on establishing an early drug discovery pipeline for small molecules targeting RNA. Antoine’s group is a key capability of THINK (THerapeutic INnovations for Kids), an initiative dedicated to generating new therapies specifically for children with cancer and moving these from the lab to the clinic as quickly as possible. Before joining Children’s Cancer Institute, Antoine worked at the Novartis Institute for BioMedical Research in Switzerland as a computational biologist in oncology.

Emeritus Professor Richard Henry AM. MB BS, Dip Clin Epi, MD, Hon DUniv (UNSW), FRACP, FRSN. Richard works as a consultant in health and higher education, following a long and distinguished career in medicine and academic leadership, including as Vice-President and Deputy Vice-Chancellor (Academic) of the University of New South Wales from 2006-2012. He joined UNSW in 1997 as the Foundation John Beveridge Professor of Paediatrics. He served as head of the School of Paediatrics and then of the School of Women’s and Children’s Health before moving to the role of Senior Associate Dean in the Faculty of Medicine. Richard was appointed a Member of the Order of Australia in 2007 for service to paediatric medicine as a clinician, researcher, educator and mentor, and serving in a range of roles with professional medical organisations. He is excited at the prospect of Luminesce Alliance as a paediatric precision medicine powerhouse able to reduce the time it previously took to deliver research findings to patients. Directorships: Director – Children’s Cancer Institute; Board member – Legal Aid NSW; Chairman of Trustees – Sydney Grammar School; Former Chair – Centre for Social Impact.

A/Prof Arndt established the ACRF Drug Discovery Centre and is currently Head of Drug Discovery Biology for the THerapeutic INnovations for Kids (THINK) initiative at Children’s Cancer Institute (CCI) and Lead for the Luminesce Alliance Advanced Therapeutics Pipeline. His recent roles include Group Leader in Cancer Therapeutics Cooperative Research Centre, and Group Leader in the Preclinical Drug Testing Core (Zero Childhood Cancer Personalised Medicine Program). A/Prof Arndt has held several university positions and is currently Associate Professor (Conjoint) in the School of Clinical Medicine (UNSW Medicine). Prior to joining CCI, he was Research Director of the Target Discovery Program at Johnson & Johnson Research, where he spent 16 years in increasingly senior roles. His research interests/expertise span target discovery and validation, development of novel technology platforms and HTS, early-stage drug discovery, development of unique cell-based platforms for personalised medicine, and translation of novel biological discoveries into the clinic.

Professor David Ziegler is an NHMRC Investigator and paediatric oncologist at the Kids Cancer Centre, Sydney Children’s Hospital, Randwick. He trained as a Fulbright Scholar at Harvard Medical School. He is Head of the Neuro-Oncology program and the Cancer Clinical Trials program at SCH. He is the Group Leader of the Brain Tumour Group at the Children’s Cancer Institute, Australia, and Conjoint Professor at the University of New South Wales. He leads Australia’s national childhood cancer personalised medicine trials through the ZERO program. He has won multiple awards including the 2023 Australian Academy of Health and Medical Sciences Jian Zhou Medal, awarded to a rising star of Australian health and medical science.